Skip to main content
SpringerLink
Log in

Amyloid Heart Disease

  • Chapter
  • First Online:
Amyloidosis

Part of the book series: Contemporary Hematology ((CH))

Abstract

Cardiac involvement in patients with amyloidosis is common. It produces significant clinical symptoms in about 40% of patients with AL amyloidosis. A significant proportion of patients with familial amyloidosis have clinical involvement of the heart, and heart failure is almost always the presenting feature of senile systemic amyloidosis. The severity of the cardiac symptoms and the response to treatment vary depending upon the type of amyloid deposition. In this chapter, the different types of cardiac amyloidosis are reviewed and the diagnostic workup and appropriate therapies are addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998 Feb;91(2):141–57.

    Article  PubMed  CAS  Google Scholar 

  2. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49(1):9–13.

    Article  PubMed  CAS  Google Scholar 

  3. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005 Jan 18;111(2):186–93.

    Article  PubMed  Google Scholar 

  4. Migrino RQ, Christenson R, Szabo A, Bright M, Truran S, Hari P. Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. BMC Med Phys. 2009 May 5;9(1):5.

    Article  PubMed  CAS  Google Scholar 

  5. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009 Feb 15;103(4):544–9.

    Article  PubMed  Google Scholar 

  6. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10(1):54.

    Article  PubMed  Google Scholar 

  7. Kribben A, Witzke O, Hillen U, Barkhausen J, Daul AE, Erbel R. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009 May 5;53(18):1621–8.

    Article  PubMed  CAS  Google Scholar 

  8. Hazenberg BP, van Rijswijk MH, Piers DA, Lub-de Hooge MN, Vellenga E, Haagsma EB, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006 Apr;119(4):355.e15–24.

    Article  PubMed  Google Scholar 

  9. Glaudemans AW, Slart RH, Zeebregts CJ, Veltman NC, Tio RA, Hazenberg BP, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009 Jan 21;36:702–14.

    Article  PubMed  CAS  Google Scholar 

  10. Pellikka PA, Holmes DR Jr., Edwards WD, Nishimura RA, Tajik AJ, Kyle RA. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988;148(3):662–6.

    Article  PubMed  CAS  Google Scholar 

  11. Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30(4):1046–51.

    Article  PubMed  CAS  Google Scholar 

  12. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation [see comments]. Br Heart J. 1995;74(5):541–4.

    Article  PubMed  CAS  Google Scholar 

  13. Feng D, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009 May 12;119(18):2490–7.

    Article  PubMed  CAS  Google Scholar 

  14. Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007 Nov 20;116(21):2420–6.

    Article  PubMed  Google Scholar 

  15. Zubkov AY, Rabinstein AA, Dispenzieri A, Wijdicks EF. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology 2007 Sep 11;69(11): 1136–41.

    Article  PubMed  Google Scholar 

  16. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr. 2004;17(1):36–44.

    Article  PubMed  Google Scholar 

  17. Koyama J, Ray-Sequin PA, Davidoff R, Falk RH. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol. 2002;89(9):1067–71.

    Article  PubMed  Google Scholar 

  18. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107(19):2446–52.

    Article  PubMed  Google Scholar 

  19. Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk RH. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005 Feb 15;95(4):538–40.

    Article  PubMed  Google Scholar 

  20. Sharma PP, Payvar S, Litovsky SH. Histomorphometric analysis of intramyocardial vessels in primary and senile amyloidosis: epicardium versus endocardium. Cardiovasc Pathol. 2008 Mar–Apr;17(2):65–71.

    Article  PubMed  Google Scholar 

  21. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006 May 15;107(10):3854–8.

    Article  PubMed  CAS  Google Scholar 

  22. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–10.

    Article  PubMed  CAS  Google Scholar 

  23. Liao RL, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104(14):1594–7.

    PubMed  CAS  Google Scholar 

  24. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 1997;78(1):74–82.

    PubMed  CAS  Google Scholar 

  25. Collins AB, Smith RN, Stone JR. Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovasc Pathol. 2008 Jul 10;18:205–16.

    Article  PubMed  CAS  Google Scholar 

  26. Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 2009 Mar;16(1):9–14.

    Article  PubMed  CAS  Google Scholar 

  27. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997 Apr 24;336(17):1202–7.

    Article  PubMed  CAS  Google Scholar 

  28. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45–59.

    PubMed  CAS  Google Scholar 

  29. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107(19):2440–5.

    Article  PubMed  CAS  Google Scholar 

  30. Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?. Am J Cardiol. 2005;96(7):982–4.

    Article  PubMed  CAS  Google Scholar 

  31. Takemura G, Takatsu Y, Doyama K, Itoh H, Saito Y, Koshiji M, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 1998;31(4):754–65.

    Article  PubMed  CAS  Google Scholar 

  32. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.

    Article  PubMed  CAS  Google Scholar 

  33. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104(6):1881–7.

    Article  PubMed  CAS  Google Scholar 

  34. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95(4):535–7.

    Article  PubMed  Google Scholar 

  35. Velazquez-Cecena JL, Lubell DL, Nagajothi N, Al-Masri H, Siddiqui M, Khosla S. Syncope from dynamic left ventricular outflow tract obstruction simulating hypertrophic cardiomyopathy in a patient with primary AL-type amyloid heart disease. Tex Heart Inst J. 2009;36(1):50–4.

    PubMed  Google Scholar 

  36. Dinwoodey DL, Skinner M, Maron MS, Davidoff R, Ruberg FL. Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Cardiol. 2008 Mar 1;101(5):674–6.

    Article  PubMed  Google Scholar 

  37. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104(2):618–20.

    Article  PubMed  CAS  Google Scholar 

  38. Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO, Higano ST, Holmes DR, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131(11): 838–41.

    PubMed  CAS  Google Scholar 

  39. Hongo M, Yamamoto H, Kohda T, Takeda M, Kinoshita O, Uchikawa S, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol. 2000;85(7):849–53.

    Article  PubMed  CAS  Google Scholar 

  40. Narang R, Chopra P, Wasir HS. Cardiac amyloidosis presenting as ischemic heart disease. A case report and review of literature. Cardiology 1993;82(4):294–300.

    Article  PubMed  CAS  Google Scholar 

  41. Mesquita T, Chorao M, Soares I, Mello e Silva A, Abecasis P. Primary amyloidosis as a cause of microvascular angina and intermittent claudication. Rev Port Cardiol. 2005 Dec;24(12):1521–31.

    PubMed  Google Scholar 

  42. Churchill CH, Abril A, Krishna M, Callman ML, Ginsburg WW. Jaw claudication in primary amyloidosis: unusual presentation of a rare disease. J Rheumatol. 2003;30(10):2283–6.

    PubMed  Google Scholar 

  43. Schneider BF, Normansell D, Ayers CR, Hess CE. Intermittent claudication as the presenting symptom in primary amyloidosis. Acta Haematologica 1993;90(2):106–7.

    Article  PubMed  CAS  Google Scholar 

  44. Yokota T, Okabayashi H, Ishihara T, Kawano H, Wakabayashi F, Miyamoto AT, et al. Immunohistochemical and pathological characteristics of dystrophic amyloid in surgically excised cardiac valves. Pathol Int. 1994;44(3):182–5.

    PubMed  CAS  Google Scholar 

  45. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008 Feb;5(2): 235–40.

    Article  PubMed  Google Scholar 

  46. Dhoble A, Khasnis A, Olomu A, Thakur R. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol. 2009 May 19;32:E63–5.

    Article  PubMed  Google Scholar 

  47. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998 May 15;91(10):3662–70.

    PubMed  CAS  Google Scholar 

  48. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004 Jan 20;140(2):85–93.

    PubMed  CAS  Google Scholar 

  49. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1083–93.

    Article  PubMed  CAS  Google Scholar 

  50. Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009 Apr;88(4):347–50.

    Article  PubMed  CAS  Google Scholar 

  51. Hosenpud JD, DeMarco T, Frazier OH, Griffith BP, Uretsky BF, Menkis AH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation 1991;84 Suppl 5:III338–43.

    Google Scholar 

  52. Hosenpud JD, Uretsky BF, Griffith BP, O’Connell JB, Olivari MT, Valantine HA. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant. 1990;9(4): 346–50.

    PubMed  CAS  Google Scholar 

  53. Dubrey S, Simms RW, Skinner M, Falk RH. Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol. 1995;76(10):739–41.

    Article  PubMed  CAS  Google Scholar 

  54. Dubrey S, Burke M, Hawkins P, Banner N. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23(10): 1142–53.

    Article  PubMed  Google Scholar 

  55. Kpodonu J, Massad MG, Caines A, Geha AS. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005 Nov;24(11): 1763–5.

    Article  PubMed  Google Scholar 

  56. Roig E, Almenar L, Gonzalez-Vilchez F, Rabago G, Delgado J, Gomez-Bueno M, et al. Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation. Am J Transplant. 2009 May 6;9:1414–9.

    Article  PubMed  CAS  Google Scholar 

  57. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006 Feb 1;107(3):1227–9.

    Article  PubMed  CAS  Google Scholar 

  58. Maurer MS, Raina A, Hesdorffer C, Bijou R, Colombo P, Deng M, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 2007 Mar 15;83(5):539–45.

    Article  PubMed  Google Scholar 

  59. Chen JM, Russo MJ, Hammond KM, Mancini DM, Kherani AR, Fal JM, et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg. 2005 Jul;80(1):224–8.

    Article  PubMed  Google Scholar 

  60. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant. 2008 Aug;27(8):823–9.

    Article  PubMed  Google Scholar 

  61. Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008 Sep;101(9):523–32.

    Article  PubMed  Google Scholar 

  62. Sack FU, Kristen A, Goldschmidt H, Schnabel PA, Dengler T, Koch A, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg. 2008 Feb;33(2):257–62.

    Article  PubMed  Google Scholar 

  63. Mignot A, Bridoux F, Thierry A, Varnous S, Pujo M, Delcourt A, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica 2008 Mar;93(3):e32–5.

    Article  Google Scholar 

  64. Audard V, Matignon M, Weiss L, Remy P, Pardon A, Haioun C, et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis. Am J Transplant. 2009 Jan;9(1):236–40.

    Article  PubMed  CAS  Google Scholar 

  65. Hess EP, White RD. Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation 2004;60(1):105–11.

    Article  PubMed  Google Scholar 

  66. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003 Sep;10(3):160–84.

    Article  PubMed  CAS  Google Scholar 

  67. Westermark P, Sletten K, Johansson B, Cornwell GG III.. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990 Apr;87(7):2843–5.

    Article  PubMed  CAS  Google Scholar 

  68. Yazaki M, Tokuda T, Nakamura A, Higashikata T, Koyama J, Higuchi K, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000 Aug 11;274(3):702–6.

    Article  PubMed  CAS  Google Scholar 

  69. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. New Engl J Med. 1997 Feb 13;336(7):466–73.

    Article  PubMed  CAS  Google Scholar 

  70. Gillmore JD, Booth DR, Pepys MB, Hawkins PN. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart (Br Card Soc). 1999 Sep;82(3):e2.

    CAS  Google Scholar 

  71. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009 May;11(3): 257–62.

    Article  PubMed  CAS  Google Scholar 

  72. Westermark P, Mucchiano G, Marthin T, Johnson KH, Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am J Pathol. 1995 Nov;147(5):1186–92.

    PubMed  CAS  Google Scholar 

  73. Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O’Grady J, Rela M, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001;71(7): 986–92.

    Article  PubMed  CAS  Google Scholar 

  74. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2009 Feb;20(2):444–51.

    Article  PubMed  CAS  Google Scholar 

  75. Mourad G, Delabre JP, Garrigue V. Cardiac amyloidosis with the E526V mutation of the fibrinogen A alpha-chain. N Engl J Med. 2008 Dec 25;359(26):2847–8.

    Article  PubMed  CAS  Google Scholar 

  76. Kiuru S, Matikainen E, Kupari M, Haltia M, Palo J. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci. 1994 Oct;126(1):40–8.

    Article  PubMed  CAS  Google Scholar 

  77. Chastan N, Baert-Desurmont S, Saugier-Veber P, Derumeaux G, Cabot A, Frebourg T, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve 2006 Jan;33(1):113–9.

    Article  PubMed  CAS  Google Scholar 

  78. Zeldenrust S, Gertz M, Uemichi T, Bjornsson J, Wiesner R, Schwab T, et al. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation 2003;75(4):560–1.

    Article  PubMed  CAS  Google Scholar 

  79. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993 May 1;341(8853):1113–6.

    Article  PubMed  CAS  Google Scholar 

  80. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation 1997 Jul 15;64(1):74–80.

    Article  PubMed  CAS  Google Scholar 

  81. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998 Jul 27;66(2):229–33.

    Article  PubMed  CAS  Google Scholar 

  82. Pomfret EA, Lewis WD, Jenkins RL, Bergethon P, Dubrey SW, Reisinger J, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation 1998 Apr 15;65(7):918–25.

    Article  PubMed  CAS  Google Scholar 

  83. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007 Jan;7(1):235–42.

    Article  PubMed  CAS  Google Scholar 

  84. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007 Dec;14(4):277–82.

    Article  PubMed  CAS  Google Scholar 

  85. Ihse E, Stangou AJ, Heaton ND, O’Grady J, Ybo A, Hellman U, et al. Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients. Biochem Biophys Res Commun. 2009 Feb 20;379(4):846–50.

    Article  PubMed  CAS  Google Scholar 

  86. Arpesella G, Chiappini B, Marinelli G, Mikus PM, Dozza F, Pierangeli A, et al. Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg. 2003 May;125(5):1165–6.

    Article  PubMed  Google Scholar 

  87. Grazi GL, Cescon M, Salvi F, Ercolani G, Ravaioli M, Arpesella G, et al. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transplant. 2003 Sep;9(9):986–92.

    Article  Google Scholar 

  88. Zeldenrust S, Gertz M, Uemichi T, Bjornsson J, Wiesner R, Schwab T, et al. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation 2003;75:560–1.

    Article  PubMed  CAS  Google Scholar 

  89. Dubrey SW, Burke MM, Hawkins PN, Banner NR. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004 Oct;23(10):1142–53.

    Article  PubMed  Google Scholar 

  90. Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O’Grady J, Rela M, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation 2001 Apr 15;71(7): 986–92.

    Article  PubMed  CAS  Google Scholar 

  91. Inomata Y, Zeledon ME, Asonuma K, Okajima H, Takeichi T, Ishiko T, et al. Whole-liver graft without the retrohepatic inferior vena cava for sequential (domino) living donor liver transplantation. Am J Transplant. 2007 Jun;7(6):1629–32.

    Article  PubMed  CAS  Google Scholar 

  92. Singer R, Mehrabi A, Schemmer P, Kashfi A, Hegenbart U, Goldschmidt H, et al. Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 cases. Transplantation 2005 Sep 27;80 Suppl 1:S156–9.

    Article  Google Scholar 

  93. Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant. 2006 Oct;6(10):2512–5.

    Article  PubMed  CAS  Google Scholar 

  94. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005 Jun 2;352(22):2356.

    Article  PubMed  CAS  Google Scholar 

  95. Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003 May;17(8):803–9.

    Article  PubMed  CAS  Google Scholar 

  96. Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti V, et al.. 4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol. 2000 Jun;156(6):1919–25.

    Article  PubMed  CAS  Google Scholar 

  97. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 1998 Oct 27;95(22):12956–60.

    Article  PubMed  CAS  Google Scholar 

  98. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Human Mutation 2001 Jun;17(6):493–503.

    Article  PubMed  CAS  Google Scholar 

  99. Oza VB, Smith C, Raman P, Koepf EK, Lashuel HA, Petrassi HM, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem. 2002 Jan 17;45(2):321–32.

    Article  PubMed  CAS  Google Scholar 

  100. Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug targets. CNS Neurol Disord. 2005 Oct;4(5):587–96.

    Article  PubMed  CAS  Google Scholar 

  101. Gillmore JD, Hawkins PN. Drug Insight: emerging therapies for amyloidosis. Nat Clin Pract Nephrol. 2006 May;2(5):263–70.

    Article  PubMed  CAS  Google Scholar 

  102. Coelho T, Coelho T, Maia L, da Silva AM, et al. A landmark clinical trial of a novel small molecule transthyretin (TTR) stabilizer, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II/III, randomized, double-blind, placebo-controlled study. Neurology 2009;72 Suppl. 3:A205.

    Article  Google Scholar 

  103. Coelho T, Waddington-Cruz M, Plante-Bordeneuve V, et al. Correlation of clinical outcomes and disease burden in patients with transthyretin (TTR) amyloid polyneuropathy: study Fx-005, a landmark clinical trail of Fx-1006A, a novel small molecule TTR stabilizer. J Neurol. 2008;255 Suppl 1:78.

    Google Scholar 

  104. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006 Dec;13(4):236–49.

    Article  PubMed  CAS  Google Scholar 

  105. Tojo K, Sekijima Y, Kelly JW, Ikeda SI. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006 Oct 5;56:441–9.

    Article  PubMed  CAS  Google Scholar 

  106. Mairal T, Nieto J, Pinto M, Almeida MR, Gales L, Ballesteros A, et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE 2009;4(1):e4124.

    Article  PubMed  CAS  Google Scholar 

  107. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545–52.

    Article  PubMed  CAS  Google Scholar 

  108. Miroy GJ, Lai Z, Lashuel HA, Peterson SA, Strang C, Kelly JW. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci USA 1996 Dec 24;93(26):15051–6.

    Article  PubMed  CAS  Google Scholar 

  109. Bergstrom J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005 Jun;206(2):224–32.

    Article  PubMed  CAS  Google Scholar 

  110. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996 Oct;101(4):395–400.

    Article  PubMed  CAS  Google Scholar 

  111. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005 Jun 27;165(12):1425–9.

    Article  PubMed  Google Scholar 

  112. Fuchs U, Zittermann A, Suhr O, Holmgren G, Tenderich G, Minami K, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant. 2005 May;5(5):1159–62.

    Article  PubMed  Google Scholar 

  113. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996 Feb 1;77(4): 313–5.

    Article  PubMed  CAS  Google Scholar 

  114. Kaye GC, Butler MG, d’Ardenne AJ, Edmondson SJ, Camm AJ, Slavin G. Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J. 1986 Oct;56(4):317–20.

    Article  PubMed  CAS  Google Scholar 

  115. Kawamura S, Takahashi M, Ishihara T, Uchino F. Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int. 1995 May;45(5):335–42.

    Article  PubMed  CAS  Google Scholar 

  116. Steiner I. The prevalence of isolated atrial amyloid. J Pathol. 1987 Dec;153(4):395–8.

    Article  PubMed  CAS  Google Scholar 

  117. Ariyarajah V, Steiner I, Hajkova P, Khadem A, Kvasnicka J, Apiyasawat S, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009;113(2):132–7.

    Article  PubMed  CAS  Google Scholar 

  118. Goette A, Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent “arrhythmogenic substrate”? Eur Heart J. 2004 Jul;25(14):1185–6.

    Article  PubMed  Google Scholar 

  119. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J. 2004 Jul;25(14):1237–41.

    Article  PubMed  CAS  Google Scholar 

  120. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol. 2006 Sep–Oct;15(5):287–90.

    Article  PubMed  CAS  Google Scholar 

  121. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002 Oct 15;106(16):2091–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Harvard Medical School, Cardiac Amyloidosis Program, Brigham and Women’s Hospital, Harvard Vanguard Medical Associates, Boston, MA, USA

    Rodney H. Falk MD, FACC

  2. Department of Cardiology, Hillingdon Hospital, Middlesex, UK

    Simon W. Dubrey MD, FRCP

Authors
  1. Rodney H. Falk MD, FACC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon W. Dubrey MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, First Street SW. 200, Rochester, 55905, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Falk, R.H., Dubrey, S.W. (2010). Amyloid Heart Disease. In: Gertz, M., Rajkumar, S. (eds) Amyloidosis. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-631-3_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-631-3_8

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-630-6

  • Online ISBN: 978-1-60761-631-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation